Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-109 in previously treated NSCLC with EGFR exon 20 insertion mutations
NCT06001671Phase 1Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of BEBT-109 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 2 years and Maximum Tolerated Dose at 2 years. Started Oct 2020; status: completed.
02
Drugs
BEBT-109
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06001671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001671.